Are recombinant human bone morphogenetic protein-7 and tobramycin compatible? An experiment in rats

Journal of Orthopaedic Trauma

Volumn 18, Issue 4, 2004, Pages 225-232

  Kawaguchi, Alan T ^a   Reddi, A Hari ^b   Olson, Steven A ^c   Yinger, Kent E ^d   Moehring, H David ^b  

^a Alpine Orthopaedic Medical Group   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NONE

Author keywords

Antibiotic beads; BMP 7; Bone formation; Tobramycin

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; BUFFER; PHOSPHATE; POLY(METHYL METHACRYLATE); RECOMBINANT OSTEOGENIC PROTEIN 1; TOBRAMYCIN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; ELUTION; ENZYME ACTIVITY; ENZYME ASSAY; EXPERIMENTAL MODEL; FRACTURE HEALING; HISTOLOGY; IN VIVO STUDY; INCUBATION TIME; MALE; MEDICAL RESEARCH; NONHUMAN; ORTHOPEDIC EQUIPMENT; OSSIFICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RAT; RISK REDUCTION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; BONE MORPHOGENETIC PROTEINS; DRUG ANTAGONISM; DRUG INCOMPATIBILITY; GROWTH SUBSTANCES; MALE; MODELS, ANIMAL; OSTEOGENESIS; RATS; TOBRAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 2342453306     PISSN: 08905339     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005131-200404000-00006     Document Type: Article

References (55)

1. Behrens FF. Fractures with soft tissue injuries. In: Browner BD, Jupiter JB, Levine AM, et al, eds. Skeletal Trauma: Fractures, Dislocations, Ligamentous Injuries. 2nd ed. Philadelphia, PA: W.B. Saunders; 1998:391-418.
2. Evans RP, Nelson CL. Gentamicin-impregnated polymethylmethacrylate beads compared with systemic antibiotic therapy in the treatment of chronic osteomyelitis. Clin Orthop. 1993;295:37-42.
3. Henry SL, Ostermann PAW, Seligson D. The prophylactic use of antibiotic impregnated beads in open fractures. J Trauma. 1990;30:1231-1238.
4. Moehring HD, Gravel C, Chapman MW, et al. Comparison of antibiotic beads and intravenous antibiotics in open fractures. Clin Orthop. 2000; 372:254-261.
5. Ostermann PAW, Henry SL, Seligson D. The role of local antibiotic therapy in the management of compound fractures. Clin Orthop. 1993; 295:102-111.
6. Seligson D, Mehta S, Voos K, et al. The use of antibiotic-impregnated polymethylmethacrylate beads to prevent the evolution of localized infection. J Orthop Trauma. 1992;6:401-406.
7. Einhorn TA, Lee CA. Bone regeneration: new findings and potential clinical applications. J Am Acad Orthop Surg. 2001;9:157-165.
8. Reddi AH. Fracture repair process: initiation of fracture repair by bone morphogenetic proteins. Clin Orthop. 1998;355S:S66-S72.
9. Reddi AH. Bone morphogenetic proteins: from basic science to clinical application. J Bone Joint Surg Am. 2001;83(suppl 1):S1-S6.
10. Bouxsein ML, Turek TJ, Blake CA, et al. Recombinant human bone morphogenetic protein-2 accelerates heating in a rabbit ulnar osteotomy model. J Bone Joint Surg Am. 2001;83:1219-1230.
11. Cook SD, Baffes GC, Wolfe MW, et al. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am. 1994;76:827-838.
12. Gerhart TN, Kirker-Head CA, Kriz MJ, et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop. 1993;293:317-326.
13. Hollinger J, Mayer M, Buck D, et al. Poly (α-hydroxy acid) carrier for delivering recombinant human bone morphogenetic protein-2 for bone regeneration. J Control Release. 1996;39:287-304.
14. Johnson EE, Urist MR, Finerman GAM. Resistant nonunions and partial or complete segmental defects of long bones: treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin Orthop. 1992;277:229-237.
15. Salkeld SL, Patron LP, Barrack RL, et al. The effect of osteogenic protein-1 on the healing of segmental bone defects treated with autograft or allograft bone. J Bone Joint Surg Am. 2001;83:803-816.
16. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83(suppl 1):S151-S158.
17. Johnson EE, Urist MR, Finerman GAM. Bone morphogenetic protein augmentation grafting of resistant femoral nonunions: a preliminary report. Clin Orthop. 1988;230:257-265.
18. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures. J Bone Joint Surg Am. 2002;84:2123-2134.
19. Ozkaynak E, Rueger DC, Drier EA, et al. OP-1 cDNA encodes an osteogenic protein in the TGF-β family. EMBO J. 1990;9:2085-2093.
20. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528-1534.
21. Lindsey RW, Probe R, Miclau T, et al. The effects of antibiotic-impregnated autogeneic cancellous bone graft on bone healing. Clin Orthop. 1993;291:303-312.
22. Reddi AH, Huggins C. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc Natl Acad Sci USA. 1972;69: 1601-1605.
23. Sampath TK, Reddi AH. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc Natl Acad Sci USA. 1981;78:7599-7603.
24. Hammonds RG Jr, Schwall R, Dudley A, et al. Bone-inducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor. Mol Endocrinol. 1991;5:149-155.
25. Reddi AH, Sullivan NE. Matrix-induced endochondral bone differentiation: influence of hypophysectomy, growth hormone, and thyroid-stimulating hormone. Endocrinology. 1980;107:1291-1299.
26. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
27. Muthukumaran S, Ma S, Reddi AH. Dose-dependence of and threshold for optimal bone induction by collagenous bone matrix and osteogenin-enriched fraction. Coll Relat Res. 1988;8:433-441.
28. Patzakis MJ, Harvey JP, Ivler D. The role of antibiotics in the management of open fractures. J Bone Joint Surg Am. 1974;56:532-541.
29. Eckman JB Jr, Henry SL, Mangino PD, et al. Wound and serum levels of tobramycin with the prophylactic use of tobramycin-impregnated polymethylmethacrylate beads in compound fractures. Clin Orthop. 1988; 237:213-215.
30. McKee MD, Wild LM, Schemitsch EH, et al. The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected lone bone defects: early results of a prospective trial. J Orthop Trauma. 2002;16:622-627.
31. Nelson CL, Griffin FM, Harrison BH, et al. In vitro elution characteristics of commercially and noncommercially prepared antibiotic PMMA beads. Clin Orthop. 1992;284:303-309.
32. Scott DM, Rotschafer JC, Behrens F. Use of vancomycin and tobramycin polymethylmethacrylate impregnated beads in the management of chronic osteomyelitis. Drug Intell Clin Pharm. 1988;22:480-483.
33. Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma. 1984;24:742-746.
34. Henry SL, Galloway KP. Local antibacterial therapy for the management of orthopaedic infections: pharmacokinetic considerations. Clin Pharmacokinet. 1995;29:36-45.
35. Chambers HF, Sande MA. Antimicrobial agents: the aminoglycosides. In: Handman JG, Limbird LE, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1103-1121.
36. Brien WW, Salvati EA, Klein R, et al. Antibiotic impregnated bone cement in total hip arthroplasty. An in vivo comparison of the elution properties of tobramycin and vancomycin. Clin Orthop. 1993;296:242-248.
37. Klemm KW. Antibiotic bead chains. Clin Orthop. 1993;295:63-76.
38. Salvati EA, Callaghan JJ, Brause BD, et al. Reimplantation in infection: elution of gentamicin from cement beads. Clin Orthop. 1986;207:83-93.
39. Wahlig H, Dingeldein E, Bergmann R, et al. The release of gentamicin from polymethylmethacrylate beads: an experimental and pharmacokinetic study. J Bone Joint Surg Br. 1978;60:270-275.
40. Goodell JA, Flick AB, Hebert JC, et al. Preparation and release characteristics of tobramycin-impregnated polymethylmethacrylate beads. Am J Hosp Pharm. 1986;43:1454-1461.
41. Adams K, Couch L, Cierny G, et al. In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop. 1992;278:244-252.
42. Becker PL, Smith RA, Williams RS, et al. Comparison of antibiotic release from polymethylmethacrylate beads and sponge collagen. J Orthop Res. 1994;12:737-741.
43. Greene N, Holtom PD, Warren CA, et al. In vitro elation of tobramycin and vancomycin polymethylmethacrylate beads and spacers from simplex and palacos. Am J Orthop. 1998;27:201-205.
44. Mader JT, Calhoun J, Cobos J. In vitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmethacrylate beads. Antimicrob Agents Chemother. 1997;41:415-418.
45. Miclau T, Dahners LE, Lindsey RW. In vitro pharmacokinetics of antibiotic release from locally implantable materials. J Orthop Res. 1993;11: 627-632.
46. Seligson D, Popham GJ, Voos K, et al. Antibiotic leaching from polymethylmethacrylate beads. J Bone Joint Surg Am. 1993;75:714-720.
47. Miclau T, Edin ML, Lester GE, et al. Bone toxicity of locally applied aminoglycosides. J Orthop Trauma. 1995;9:401-406.
48. Bostrom M, Lane JM, Tomin E, et al. Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Clin Orthop. 1996;327:272-282.
49. Cook SD, Baffes GC, Wolfe MW, et al. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop. 1994;301:302-312.
50. Cook SD, Salkeld SL, Brinker MR, et al. Use of an osteoinductive biomaterial (rhOP-1) in healing large segmental bone defects. J Orthop Trauma. 1998;12:407-412.
51. Cook SD, Wolfe MW, Salkeld SL, et al. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am. 1995;77:734-750.
52. Stevenson S, Cunningham N, Toth J, et al. The effect of osteogenin (a bone morphogenetic protein) on the formation of bone in orthotopic segmental defects in rats. J Bone Joint Surg Am. 1994;76:1676-1687.
53. Johnson EE, Urist MR, Finerman GAM. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein: a preliminary report. Clin Orthop. 1988;236:249-257.
54. Bostrom MPG, Camacho NP. Potential role of bone morphogenetic proteins in fracture healing. Clin Orthop. 1998;355S:S274-S282.
55. Calhoun JH, Henry SL, Anger DM, et al. The treatment of infected nonunions with gentamicin-polymethylmethacrylate antibiotic beads. Clin Orthop. 1993;295:23-27.